•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.aTyr Pharma to Participate in Upcoming Investor Conferences
aTyr Pharma Announces Publication of Results from the Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis in The Lancet Respiratory Medicine
aTyr Pharma Announces One-for-40 Reverse Stock Split
aTyr Pharma Announces Research Collaboration with Montefiore Einstein
aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological Chemistry
Financial Contrast: MeiraGTx (NASDAQ:MGTX) & aTyr Pharma (NASDAQ:ATYR)
Positive FDA Alignment Boosts ATyr Pharma's Rare Lung Disease
aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD
aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026
aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update
aTyr Pharma to Participate in Upcoming Investor Conferences
aTyr Pharma, Inc. (ATYR) Discusses FDA Feedback and Next Steps for Efzofitimod in Pulmonary Sarcoidosis After Phase III Results Transcript
aTyr Pharma Revamps Efzofitimod Path With New Phase III Sarcoidosis Trial
aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting
aTyr Pharma Spotlights Efzofitimod Phase 3 Learnings, Eyes Mid-April FDA Type C Meeting
aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update
aTyr Pharma (NASDAQ:ATYR) Trading Down 2.1% – Should You Sell?
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)